HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

butabindide

structure given in first source

Also Known As:

UCL 1397; UCL-1397

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - butabindide: 2

Experts

1.	Florea, Bogdan: 1 article (08/2015)
2.	Kessels, Helmut W: 1 article (08/2015)
3.	Ovaa, Huib: 1 article (08/2015)
4.	Overkleeft, Herman S: 1 article (08/2015)
5.	Raspe, Marcel A: 1 article (08/2015)
6.	Reits, Eric A: 1 article (08/2015)
7.	Renner, Maria C: 1 article (08/2015)
8.	Stap, Jan: 1 article (08/2015)
9.	Stargardt, Anita: 1 article (08/2015)
10.	Tomkinson, Birgitta: 1 article (08/2015)

Related Diseases

1.	Neuroblastoma 08/01/2015 - "We identified rapid proteomic changes in neuroblastoma cells following selective TPP2 inhibition using the known reversible inhibitor butabindide, as well as a new, more potent, and irreversible peptide phosphonate inhibitor. "
2.	Burkitt Lymphoma (Burkitt's Lymphoma) 09/01/2010 - "Remarkably, the potent and selective TPPII inhibitor butabindide not only potently suppressed centriole aberrations but also caused significant cell death and growth suppression in aggressive human Burkitt lymphoma cells with c-MYC overexpression. "

Related Drugs and Biologics

1.	Organophosphonates (Phosphonates)
2.	Peptides (Polypeptides)